表紙
市場調查報告書

多發性骨髓瘤 - 全球治療藥市場預測及分析 ∼2027年

Multiple Myeloma: Global Drug Forecast and Market Analysis to 2027

出版商 GlobalData 商品編碼 876680
出版日期 內容資訊 英文 164 Pages
訂單完成後即時交付
價格
多發性骨髓瘤 - 全球治療藥市場預測及分析 ∼2027年 Multiple Myeloma: Global Drug Forecast and Market Analysis to 2027
出版日期: 2019年03月29日內容資訊: 英文 164 Pages
簡介

全球主要8國的多發性骨髓瘤治療藥市場在2017年達145億美元規模,預估之後將以6.7%的CAGR (複合年均成長率) 持續成長,於2027年達278億美元規模。

本報告研究全球多發性骨髓瘤 (MM) 治療藥市場,彙整疾病概要及流行病學背景、發病者數動向展望、臨床進行情況、已上市/臨床試驗中的主要治療藥、目前市場的未滿足需求、主要企業簡介、全球/主要國家市場趨勢展望等情報。

第1章 目錄

第2章 摘要整理

第3章 簡介

第4章 疾病概要

  • 病因學和病理生理學
    • 病因學
    • 病理生理學
    • 預後
    • 生活品質 (QoL)

第5章 流行病學

  • 疾病背景
  • 風險因素和合併症
  • 全球和歷史趨勢
    • 多發性骨髓瘤 (MM) 診斷髮病者數
  • 預測方法
    • 情報來源
    • 預測假設和方法
  • 多發性骨髓瘤的流行病學預測 (共11年)
    • 多發性骨髓瘤診斷髮病件數 (總數)
    • 多發性骨髓瘤診斷髮病件數:按年齡
    • 多發性骨髓瘤診斷髮病件數:按性別
    • 多發性骨髓瘤診斷髮病件數:按目前症狀
    • 多發性骨髓瘤診斷髮病件數:按幹細胞移植 (SCT) 適格性
    • 多發性骨髓瘤診斷髮病件數:按染色體異常狀態
    • 多發性骨髓瘤診斷髮病件數:按R-ISS (病期分類)
    • 多發性骨髓瘤診斷髮病者數
  • 討論
    • 流行病學預測考察
    • 分析限制
    • 分析強項

第6章 疾病管理

  • 診斷和治療概要
  • 美國
    • 診斷
    • 臨床診療
  • 歐洲主要5國 (5EU:法國、德國、義大利、西班牙、英國)
  • 日本
  • 中國

第7章 競爭評估

  • 概要

第8章 未滿足需求及市場機會分析

  • 概要
  • 細胞遺傳學之高風險病患治療方法改善
  • 透過細胞遺傳學特性的個人化治療方法
  • 針對高強度治療病患的治療法
  • 改善投藥路徑

第9章 Pipeline評估

  • 概要
  • 臨床開發中的潛力藥物

第10章 現在及未來的市場投入企業

  • 概要
  • 企業策略趨勢
  • 武田藥品工業
    • 投資組合評估
  • BMS and Celgene
  • Amgen
  • J&J
  • Novartis
  • Sanofi
  • AbbVie and Roche
  • GSK
  • Karyopharm

第11章 市場未來展望

  • 全球市場
    • 市場預測
    • 市場推動及阻礙因素:全球課題
  • 美國
    • 未來預測
    • 關鍵事件
    • 市場推動及阻礙因素
  • 歐洲主要5國 (5EU)
  • 日本
  • 中國

第12章 附錄

目錄
Product Code: GDHC175PIDR

The Multiple Myeloma (MM) market is expected to grow from $14.5bn in 2017 to $27.8bn by 2027 across the 8 major markets (US, France, Germany, Italy, Spain, UK, Japan, and China) at a compound annual growth rate (CAGR) of 6.7%. The modest growth of the Multiple Myeloma (MM) market will be driven by increasing prevalence, primarily by aging populations, as well as the approval and launch of new branded therapies. In addition, label expansion of currently marketed therapies: Darzalex, Kyprolis, Pomalyst, Ninlaro, and Empliciti will promote market growth during the forecast period.

BCMA-targeting class of therapies is highly anticipated in Multiple Myeloma (MM) and they are expected to improve treatment outcome in heavily-treated patients, an area of major unmet need in Multiple Myeloma (MM). It is expected to result in significant revenues due to premium pricing and clinical benefit in heavily pretreated patients. This class will be represented by four drug candidates, BCMA CAR-Ts bb2121 and JNJ-4528, the bispecific T-cell engager AMG 420, and the antibody-drug conjugate GSK2857916. The combined revenue of all four therapies is expected to reach $10bn in 2027.

Generic and biosimilar erosion of some of the mainstays of Multiple Myeloma (MM) treatment is also expected between 2017 and 2027. A major barrier for market growth in Multiple Myeloma (MM) will be the increased use of generics, in particular generic lenalidomide. The branded Revlimid alone brought in around $6.1bn in the US in 2018. Patent expiry is also expected for other major current standards of treatment, Velcade, Kyprolis, Pomalyst, Ninlaro, and Darzalex, during the forecast period. Generic and biosimilar erosion is expected to temper market growth significantly.

The company's latest report, 'Multiple Myeloma: Global Drug Forecast and Market Analysis to 2027', states that the main driver of growth in the global Multiple Myeloma (MM) market for the next ten years will be the approval and launch of pipeline therapies in multiple treatment lines.

Key Questions Answered by the report -

  • Which pipeline agents are the most promising and expected to launch in the 8 major markets? What are the forecasted sales of these agents and what will be their impact in the Multiple Myeloma (MM) market?
  • What are the main unmet needs in Multiple Myeloma (MM), which pipeline drugs will fulfill these needs, and to what extent?
  • What are the current research and development (R&D) strategies being explored and how can developers incorporate these methods into their business strategy?
  • Key Opinions Leaders (KOLs) insights across the 8 major markets, relating to the current treatment options and opinions on the late and early stage pipeline agents.

Scope

  • Overview of MM, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.
  • Annualized MM therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in eight geographic regions, forecast from 2017 to 2027. Hybrid forecast model: incidence & prevalence.
  • Key topics covered include strategic competitive assessment, market characterization, unmet needs, clinical trial mapping and implications for the MM therapeutics market.
  • Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for MM. The most promising candidates in late-stage development are profiled.
  • Analysis of the current and future market competition in the global MM market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

The report will enable you to -

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global MM market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global MM market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Table of Contents

  • 1 Table of Contents
    • 1.1 List of Tables
    • 1.2 List of Figures
  • 2 Multiple Myeloma: Executive Summary
    • 2.1 Multiple Myeloma Market Is Expected to Grow to $21.6B in 2027
    • 2.2 Multiple Myeloma Pipeline Is Diverse, Comprising Therapies with Novel Mechanisms of Action
    • 2.3 Opportunities Remain for More Effective and Conveniently Administered Therapies in Multiple Myeloma
    • 2.4 Anti-BCMA Biologics Are Best Equipped to Penetrate the Multiple Myeloma Market
    • 2.5 What Do Physicians Think?
  • 3 Introduction
    • 3.1 Catalyst
    • 3.2 Related Reports
    • 3.3 Upcoming Related Reports
  • 4 Disease Overview
    • 4.1 Etiology and Pathophysiology
      • 4.1.1 Etiology
      • 4.1.2 Pathophysiology
    • 4.2 Classification or Staging Systems
  • 5 Epidemiology
    • 5.1 Disease Background
    • 5.2 Risk Factors and Comorbidities
    • 5.3 Global and Historical Trends
      • 5.3.1 Diagnosed Incidence of MM
    • 5.4 Forecast Methodology
      • 5.4.1 Sources Used
      • 5.4.2 Forecast Assumptions and Methods
      • 5.4.3 Diagnosed Incident Cases of MM
      • 5.4.4 Diagnosed Incident Cases of MM by Symptom Status
      • 5.4.5 Diagnosed Incident Cases of MM by SCT Eligibility
      • 5.4.6 Diagnosed Incident Cases of MM by Chromosomal Abnormalities
      • 5.4.7 Diagnosed Incident Cases of MM by R-ISS Staging
      • 5.4.8 Diagnosed Prevalent Cases of MM
    • 5.5 Epidemiological Forecast for Multiple Myeloma (2017-2027)
      • 5.5.1 Diagnosed Incident Cases of MM
      • 5.5.2 Age-Specific Diagnosed Incident Cases of MM
      • 5.5.3 Sex-Specific Diagnosed Incident Cases of MM
      • 5.5.4 Diagnosed Incident Cases of MM by Symptom Status
      • 5.5.5 Diagnosed Incident Cases of MM by SCT Eligibility
      • 5.5.6 Diagnosed Incident Cases of MM by Chromosomal Abnormalities
      • 5.5.7 Diagnosed Incident Cases of MM by R-ISS Staging
      • 5.5.8 Diagnosed Prevalent Cases of MM
    • 5.6 Discussion
      • 5.6.1 Epidemiological Forecast Insight
      • 5.6.2 Limitations of Analysis
      • 5.6.3 Strengths of Analysis
  • 6 Disease Management
    • 6.1 Diagnosis and Treatment Overview
    • 6.2 US
      • 6.2.1 Diagnosis
      • 6.2.2 Clinical Practice
    • 6.3 5EU
      • 6.3.1 France
      • 6.3.2 Germany
      • 6.3.3 Italy
      • 6.3.4 Spain
      • 6.3.5 UK
      • 6.3.6 Japan
      • 6.3.7 China
  • 7 Competitive Assessment
    • 7.1 Overview
  • 8 Unmet Needs and Opportunity Assessment
    • 8.1 Overview
    • 8.2 Improved Treatments for Patients with High-Risk Cytogenetics
    • 8.3 Personalized Approach to Treatment Using Cytogenetic Profiles
    • 8.4 Treatment of Heavily Pretreated Patients
    • 8.5 Improved Route of Administration
  • 9 Pipeline Assessment
    • 9.1 Overview
    • 9.2 Promising Drugs in Clinical Development
  • 10 Current and Future Players
    • 10.1 Overview
    • 10.2 Trends in Corporate Strategy
    • 10.3 Takeda Portfolio Assessment
    • 10.4 BMS and Celgene Portfolio Assessment
    • 10.5 Amgen Portfolio Assessment
    • 10.6 J&J Portfolio Assessment
    • 10.7 Novartis Portfolio Assessment
    • 10.8 Sanofi Portfolio Assessment
    • 10.9 AbbVie and Roche Portfolio Assessment
    • 10.10 GSK Portfolio Assessment
    • 10.11 Karyopharm Portfolio Assessment
  • 11 Market Outlook
    • 11.1 Global Markets
      • 11.1.1 Forecast
      • 11.1.2 Drivers and Barriers - Global Issues
    • 11.2 US
      • 11.2.1 Forecast
      • 11.2.2 Key Events
      • 11.2.3 Drivers and Barriers
    • 11.3 5EU
      • 11.3.1 Forecast
      • 11.3.2 Key Events
      • 11.3.3 Drivers and Barriers
    • 11.4 Japan
      • 11.4.1 Forecast
      • 11.4.2 Key Events
      • 11.4.3 Drivers and Barriers
    • 11.5 China
      • 11.5.1 Forecast
      • 11.5.2 Key Events
      • 11.5.3 Drivers and Barriers
  • 12 Appendix
    • 12.1 Bibliography
    • 12.2 Abbreviations
    • 12.3 Methodology
      • 12.3.1 Forecasting Methodology
      • 12.3.2 Diagnosed Patients
      • 12.3.3 Percent Drug-Treated Patients
      • 12.3.4 Drugs Included in Each Therapeutic Class
      • 12.3.5 Launch and Patent Expiry Dates
      • 12.3.6 General Pricing Assumptions
      • 12.3.7 Individual Drug Assumptions
      • 12.3.8 Generic/Biosimilar Erosion
      • 12.3.9 Pricing of Pipeline Agents
    • 12.4 Primary Research - KOLs Interviewed for This Report
      • 12.4.1 KOLs
    • 12.5 Primary Research - Prescriber Survey
    • 12.6 About the Authors
      • 12.6.1 Analyst
      • 12.6.2 Therapy Area Director
      • 12.6.3 Epidemiologist
      • 12.6.4 Reviewers
      • 12.6.5 Global Director of Therapy Analysis and Epidemiology
      • 12.6.6 Global Head and EVP of Healthcare Operations and Strategy
    • 12.7 About GlobalData
    • 12.8 Contact Us
    • 12.9 Disclaimer

List of Tables

  • Table 1: Multiple Myeloma: Key Metrics in the 8MM
  • Table 2: Disease Manifestation in Multiple Myeloma
  • Table 3: DS and ISS Systems and Their Relationships to Disease Stage
  • Table 4: Risk Factors for MM
  • Table 5: Treatment Guidelines for Multiple Myeloma
  • Table 6: Country Profile - US
  • Table 7: Country Profile - France
  • Table 8: Country Profile - Germany
  • Table 9: Country Profile - Italy
  • Table 10: Country Profile - Spain
  • Table 11: Country Profile - UK
  • Table 12: Country Profile - Japan
  • Table 13: Country Profile - China
  • Table 14: Leading Treatments for Multiple Myeloma, 2019
  • Table 15: Takeda's Multiple Myeloma Portfolio Assessment, 2019
  • Table 16: BMS and Celgene's Multiple Myeloma Portfolio Assessment, 2019
  • Table 17: Amgen's Multiple Myeloma Portfolio Assessment, 2019
  • Table 18: J&J's Multiple Myeloma Portfolio Assessment, 2019
  • Table 19: Novartis' Multiple Myeloma Portfolio Assessment, 2019
  • Table 20: Sanofi's Multiple Myeloma Portfolio Assessment, 2019
  • Table 21: AbbVie and Roche's Multiple Myeloma Portfolio Assessment, 2019
  • Table 22: GSK's Multiple Myeloma Portfolio Assessment, 2019
  • Table 23: Karyopharm's Multiple Myeloma Portfolio Assessment, 2019
  • Table 24: Multiple Myeloma Market - Global Drivers and Barriers, 2017-2027
  • Table 25: Key Events Impacting Sales for Multiple Myeloma in the US, 2017-2027
  • Table 26: Multiple Myeloma Market - Drivers and Barriers in the US, 2017-2027
  • Table 27: Key Events Impacting Sales for Multiple Myeloma in the 5EU, 2017-2027
  • Table 28: Multiple Myeloma Market - Drivers and Barriers in the 5EU, 2017-2027
  • Table 29: Key Events Impacting Sales for Multiple Myeloma in Japan, 2017-2027
  • Table 30: Multiple Myeloma Market - Global Drivers and Barriers in Japan, 2017-2027
  • Table 31: Key Events Impacting Sales for Multiple Myeloma in China, 2017-2027
  • Table 32: Multiple Myeloma Market - Global Drivers and Barriers in China, 2017-2027
  • Table 33: Key Historical and Projected Launch Dates for MM
  • Table 34: Key Historical and Projected Patent Expiry Dates for MM
  • Table 35: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

List of Figures

  • Figure 1: Global Sales Forecast by Country for Multiple Myeloma in 2017 and 2027
  • Figure 2: Analysis of the Company Portfolio Gap in Multiple Myeloma During the Forecast Period
  • Figure 3: Competitive Assessment of the Pipeline Agents that GlobalData Expects to be Licensed for the Treatment of Multiple Myeloma During the Forecast Period
  • Figure 4: 8MM, Age-Standardized Diagnosed Incidence of MM (Cases per 100,000 Population), Men, Ages ≥40 Years, 2007 to 2027
  • Figure 5: 8MM, Age-Standardized Diagnosed Incidence of MM (Cases per 100,000 Population), Women, Ages ≥40 Years, 2007 to 2027
  • Figure 6: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of MM
  • Figure 7: 8MM, Sources Used to Forecast the Diagnosed Prevalent Cases of MM
  • Figure 8: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of MM by Symptom Status
  • Figure 9: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of MM by SCT Eligibility
  • Figure 10: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of MM by Chromosomal Abnormalities
  • Figure 11: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of MM by R-ISS Staging
  • Figure 12: 8MM, Diagnosed Incident Cases of MM, Both Sexes, Ages ≥40 Years, N, 2017
  • Figure 13: 8MM, Age-Specific Diagnosed Incident Cases of MM, Both Sexes, Ages ≥40 Years, N, 2017
  • Figure 14: 8MM, Sex-Specific Diagnosed Incident Cases of MM, Ages ≥40 Years, N, 2017
  • Figure 15: 8MM, Diagnosed Incident Cases of MM by Symptom Status, Both Sexes, Ages ≥40 Years, N, 2017
  • Figure 16: 8MM, Diagnosed Incident Cases of MM by SCT Eligibility, Both Sexes, Ages ≥40 Years, N, 2017
  • Figure 17: 8MM, Diagnosed Incident Cases of MM by Chromosomal Abnormalities, Both Sexes, Ages ≥40 Years, N, 2017
  • Figure 18: 8MM, Diagnosed Incident Cases of MM by R-ISS Staging, Both Sexes, Ages ≥40 Years, N, 2017
  • Figure 19: 8MM, Diagnosed Prevalent Cases of MM, Both Sexes, Ages ≥40 Years, N, 2017
  • Figure 20: Patient Journey for SCT-e and SCT-I NDMM
  • Figure 21: Patient Journey for RRMM
  • Figure 22: Unmet Needs and Opportunities in Multiple Myeloma
  • Figure 23: Overview of the Development Pipeline in Multiple Myeloma
  • Figure 24: Key Phase I-II-III Trials for the Promising Pipeline Agents That GlobalData Expects to Be Licensed for Multiple Myeloma in the 8MM During the Forecast Period
  • Figure 25: Competitive Assessment of the Pipeline Agents That GlobalData Expects to Be Licensed for the Treatment of Multiple Myeloma During the Forecast Period
  • Figure 26: Analysis of the Company Portfolio Gap in Multiple Myeloma During the Forecast Period
  • Figure 27: Global (8MM) Sales Forecast by Country for Multiple Myeloma, 2017 and 2027
  • Figure 28: Global (8MM) Sales Forecast by Therapy Class for Multiple Myeloma, 2017 and 2027
  • Figure 29: Sales Forecast by Class for Multiple Myeloma in the US in 2017 and 2027
  • Figure 30: Sales Forecast by Class for Multiple Myeloma in the 5EU in 2017 and 2027
  • Figure 31: Sales Forecast by Class for Multiple Myeloma in Japan in 2017 and 2027
  • Figure 32: Sales Forecast by Class for Multiple Myeloma in China in 2017 and 2027